Multiple myeloma is a dubious disease in the field of the nervous system, with complex clinical outcomes and often involving multiple systemic strain. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
Platforms can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Individual development of treatment and management of multiple myeloma treatment plans, usually including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many of the neurological diseases that have been difficult to treat have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of multiple myeloma. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of neural systems, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.